M1RN34:BVMF
Moderna
50,55 BRL
0,00%
(0,00) 1 д.
5.10, 17:08:00 ч. Гринуич-3 · BRL
search
Всички символи
| Символ | Цена | Промяна | % промяна |
|---|
insights_autoГенерира се водещата статистика за M1RN34…
Отваряне
47,01 BRL
Висока
51,35 BRL
Ниска
46,36 BRL
Пазарна кап.
81,13 млрд.
Ср. обем
131,02 хил.
Обем
128,26 хил.
Най-висока цена за 52 седм.
54,38 BRL
Най-ниска цена за 52 седм.
6,02 BRL
Акции в обращение
399,24 млн.
Брой служители
5 хил.
Отваряне
47,01 BRL
Висока
51,35 BRL
Ниска
46,36 BRL
Пазарна кап.
81,13 млрд.
Ср. обем
131,02 хил.
Обем
128,26 хил.
Най-висока цена за 52 седм.
54,38 BRL
Най-ниска цена за 52 седм.
6,02 BRL
Акции в обращение
399,24 млн.
Брой служители
5 хил.
Новинарски материали
От източници в мрежата и новинарски партньори
Stock Titan
·
преди 2 часа
Moderna (MRNA) COO Juan Andres reports direct ownership of 125,000 common shares.
Kalkine Media
·
преди 7 часа
Why is Moderna (NASDAQ:MRNA) stock surging as cancer vaccine optimism builds?
TradingKey
·
преди 8 часа
Moderna Inc Stock (MRNA) Moved Up by 5.71% on Oct 5: What Investors Need To Know
Yahoo Finance
·
преди 22 часа
Moderna (MRNA) Soars 175% in Q3: Can The Stock Keep Running?
Профил
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
The company's commercial products are the Moderna COVID-19 vaccine sold under the brand names Spikevax and Mnexspike, a respiratory syncytial virus vaccine sold under the brand name Mresvia, and an influenza vaccine sold under the brand name Mflusiva. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.
In May 2026, Time ranked Moderna first in their list of the World's Most Impactful Companies. Wikipedia
Всичко за Moderna
Главен изпълнителен директорСтефан Бансел
Служители4,7 хил.
Дата на основаванесеп 2010
Централен офис-
Бранш-
Уебсайтmodernatx.com